BJH: Can nivolumab alone cure patients with relapsed or refractory Hodgkin lymphoma?

 Checkpoint blockade with (PD-1) monotherapy has shown promising efficacy in patients with relapsed/refractory Hodgkin lymphoma (R/R HL)

 Checkpoint blockade with (PD-1) monotherapy has shown promising efficacy in patients with relapsed/refractory Hodgkin lymphoma (R/R HL)

It has been suggested that younger patients with early and deep responses are more likely to be relapse-free 1 year after anti-PD-1 discontinuation

Here, we report a 5-year analysis of the ATU-nivo study, a retrospective nationwide study visit program in R/R HL patients ≥18 years of age who received nivolumab early in France ( EAP)

Seventy-six patients were included in the efficacy analysis

To assess whether some patients could be cured with nivolumab alone as systemic therapy, the research team analyzed 19 patients who achieved a CR without consolidation therapy (5 patients had concomitant radiation therapy)

After a median follow-up of 5.

Nivolumab 1

Figure 1: Progression-free survival (PFS; blue) and overall survival (OS; red) in patients with complete remission (CR) on nivolumab monotherapy without concomitant/consolidation therapy (radiation allowed)

Figure 1: Progression-free survival (PFS; blue) and overall survival (OS; red) in patients with complete remission (CR) on nivolumab monotherapy without concomitant/consolidation therapy (radiation allowed) Figure 1: Progression-free survival (PFS; blue) and overall survival (OS; red) in patients with complete remission (CR) on nivolumab monotherapy without concomitant/consolidation therapy (radiation allowed)

Nine patients relapsed, six of whom received salvage therapy: three received a second course of anti-PD-1, and three received radiotherapy and/or chemotherapy

Nivolumab

In total, two patients died: one from metastatic colorectal cancer (6 months after initiation of nivolumab) and one from coronavirus disease 2019 (COVID-19)

n

Overall, this was the longest follow-up reported in this setting

n

In conclusion, this study confirms that, after long-term follow-up, nivolumab is an effective strategy in this heavily pretreated population

After long-term follow-up, nivolumab was an effective strategy in this heavily pretreated population

Original source:

Original source:

Manson, G.

Manson, G.
, Herbaux, C.
, Schiano, J.
-M.
, Casasnovas, O.
, Stamatoullas, A.
, Deau, B.
, Schmitt, A.
, Regny, C.
, Bouabdallah, K.
, Chauchet, A.
, Ghesquieres, H.
, Tempescul, A.
, Dulery, R.
, Nicolas-Virelizier, E.
, Delmer, A.
, Borel, C.
, Dercle, L.
, Brice, P.
, Houot, R.
and (2022), Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
Br J Haematol.
https://doi.
org/10.
1111/bjh.
18198Manson, G.
, Herbaux, C.
, Schiano, J.
-M.
, Casasnovas, O.
, Stamatoullas, A.
, Deau, B.
, Schmitt, A.
, Regny, C.
, Bouabdallah, K.
, Chauchet, A.
, Ghesquieres, H.
, Tempescul, A.
, Dulery, R.
, Nicolas-Virelizier, E.
, Delmer, A.
, Borel, C.
, Dercle, L.
, Brice, P.
, Houot, R.
and (2022), Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
Br J Haematol.
https://doi.
org/10.
1111/bjh.
18198

here message